FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 461 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 Body Location May Influence Fate of Cells with Cancer-Causing Mutations April 29, 2022 COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... May 8, 2020 Load more HOT NEWS Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... Seeing a Promising Future for Progress against Childhood Cancer Cancer in My Community: Working to Eliminate the Stigma of Cancer... FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC...
